NASDAQ:VYGR
Voyager Therapeutics, Inc.
Voyager Therapeutics, Inc.'s revenue fell 49.5% in fiscal 2025 to $40.4M while operating margin fell to −326.6%. Free cash flow was −$135.1M, −334.5% of revenue, and the diluted share count rose 1.8%.Summary generated from Voyager Therapeutics, Inc.'s SEC filings. Latest annual report filed Mar 9, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$40.4M
Revenue growth−49.5%
Revenue, 5-yr CAGR−25.1%
Gross marginn/a
Operating margin−326.6%
Net margin−296.5%
ROICn/a
Return on equity−48.3%
Debt / equityn/a
Free cash flow−$135.1M
FCF margin−334.5%
Share count change+1.8%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 37 | 41 | 250 | 80 | 40 |
| Operating income | −74 | −51 | 122 | −83 | −132 |
| Net income | −71 | −46 | 132 | −65 | −120 |
| Free cash flow | −55 | −15 | 75 | −19 | −135 |
Recent filings
- 8-KResults of operations and financial condition
Aug 6, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 6, 2026 - 8-KOther events
Jul 13, 2026 - 4Insider transaction report
Jun 11, 2026 - 4Insider transaction report
Jun 11, 2026 - 8-KAmendment to articles or bylaws
Jun 10, 2026 - 8-KOther events
Jun 1, 2026 - 8-KResults of operations and financial condition
May 7, 2026